Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy

Next Previous
Trial Profile

A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efavaleukin alfa (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Amgen

    • Most Recent Events

    • 11 Sep 2019 Planned End Date changed from 16 Mar 2023 to 15 Jun 2023.
    • 11 Sep 2019 Planned primary completion date changed from 16 Mar 2023 to 15 Jun 2023.
    • 14 Aug 2019 Planned End Date changed from 11 May 2023 to 16 Mar 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top